Skip to main content

Table 3 Description and levels of concern of the IMD patient community

From: The impact of COVID-19 on rare metabolic patients and healthcare providers: results from two MetabERN surveys

Description of concern

Level of concern

Not worried at all

Somewhat worried

Neither worried nor unworried

Worried

Extremely worried

Having the therapy suspended

1/3

(2.8)

8/36

(22.2)

3/36

(8.3)

14/36

(38.9)

10/36

(27.8)

Not having access to the same standard quality of care as before

2/36

(5.6)

2/36

(5.6)

6/36

(16.7)

16/36

(44.4)

10/36

(27.8)

Anxiety and mental health issues related with the quarantine and current medical care limitations

0/35

(0)

6/35

(17.1)

6/35

(17.1)

18/35

(51.4)

5/35

(14.3)

Possibility of getting COVID-19

0/35

(0)

4/35

(11.4)

2/35

(5.7)

12/35

(34.3)

17/355

(48.6)

Additional strain being put on family caregivers

0/34

(0)

5/34

(14.7)

3/34

(8.8)

19/34

(55.9)

7/34

(20.6)

Patients/caregivers not having access to reliable and comprehensible information

5/36

(13.9)

6/36

(16.7)

10/36

(27.8)

9/36

(25)

6/36

(16.7)